UBS Group
NRSN icon

UBS Group’s NeuroSense Therapeutics NRSN Stock Holding History

UBS Group’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.1K Buy
49,096
+18,225
+59% +$16.3K ﹤0.01% 7557
2025
Q4 		$23.7K Buy
30,871
+16,212
+111% +$17.1K ﹤0.01% 7666
2025
Q3 		$18.3K Buy
14,659
+13,048
+810% +$19.1K ﹤0.01% 8210
2025
Q2 		$3.04K Sell
1,611
-664
-29% -$962 ﹤0.01% 9391
2025
Q1 		$2.12K Buy
+2,275
New +$2.52K ﹤0.01% 9386
2024
Q2 		– Sell
-11,928
Closed -$21.7K – 9920
2024
Q1 		$21.7K Buy
11,928
+6,432
+117% +$8.66K ﹤0.01% 6892
2023
Q4 		$4.31K Sell
5,496
-4,169
-43% -$2.77K ﹤0.01% 7877
2023
Q3 		$6.86K Buy
+9,665
New +$10.1K ﹤0.01% 7266
2023
Q2 		– Sell
-4,762
Closed -$8.19K – 9407
2023
Q1 		$8.19K Buy
4,762
+697
+17% +$1.16K ﹤0.01% 7748
2022
Q4 		$4.96K Buy
4,065
+2,238
+122% +$3.56K ﹤0.01% 9238
2022
Q3 		$3K Sell
1,827
-11,601
-86% -$23.8K ﹤0.01% 9562
2022
Q2 		$45K Buy
13,428
+11,544
+613% +$21.9K ﹤0.01% 6003
2022
Q1 		$7K Sell
1,884
-6,134
-77% -$14.6K ﹤0.01% 8829
2021
Q4 		$20K Buy
+8,018
New +$24.4K ﹤0.01% 7843

Other funds holding NRSN

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

UBS Group's NRSN Position: Q1 2026 in Review

UBS Group increased its NeuroSense Therapeutics (NRSN) stake by 59% in Q1 2026, buying an estimated $16.3K and bringing the position to 49,096 shares worth $37.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7557.

UBS Group first reported a position in NRSN in Q4 2021 and has held it in 14 quarters since. The position peaked at $45K in Q2 2022. 13 funds tracked by Wall St. Rank hold NRSN as of Q1 2026.

  • UBS Group held 49,096 shares of NeuroSense Therapeutics worth $37.1K as of Q1 2026.
  • UBS Group bought 18,225 NeuroSense Therapeutics shares in Q1 2026, an estimated $16.3K.
  • NeuroSense Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7557 holding.
  • UBS Group first reported a position in NeuroSense Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • UBS Group's NeuroSense Therapeutics position peaked at $45K in Q2 2022.
  • 13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.